Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing

• Type of Material: Article
• Authors: Alejandra Rojas, Universidad Nacional de Asunción; Muktha S Natrajan, Emory University; Jenna Weber, Stanford University; Fátima Cardozo, Universidad Nacional de Asunción; César Cantero, Universidad Nacional de Asunción; Jeyarama S Ananta, Nirmidas Biotech Inc; Jessica Kost, Nirmidas Biotech Inc; Meijie Tang, Nirmidas Biotech Inc; Sanny López, Universidad Nacional de Asunción; Cynthia Bernal, Universidad Nacional de Asunción; Yvalena Guillen, Universidad Nacional de Asunción; Laura Mendoza, Universidad Nacional de Asunción; Malvina Paez, Universidad Nacional de Asunción; Benjamin A Pinsky, Stanford University; Jesse Waggoner, Emory University
• Language: English
• Date: 2021-05-01
• Publisher: AMER SOC TROP MED & HYGIENE
• Publication Version: Final Published Version
• Copyright Statement: © The American Society of Tropical Medicine and Hygiene
• Final Published Version (URL): http://dx.doi.org/10.4269/ajtmh.20-1449
• Title of Journal or Parent Work: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
• Volume: 104
• Issue: 5
• Start Page: 1729
• End Page: 1733
• Keywords: Tropical Medicine; VIRUS-INFECTION; DEPENDENT ENHANCEMENT; REVERSE TRANSCRIPTION-PCR; SINGLE-REACTION; Public, Environmental & Occupational Health; ANTIBODIES; Science & Technology; MOLECULAR EPIDEMIOLOGY; CHIKUNGUNYA; PARAGUAY; RESPONSES; Life Sciences & Biomedicine; MULTIPLEX
• Research Categories: Health Sciences, Pathology; Health Sciences, Public Health

Abstract

Antibody cross-reactivity confounds testing for dengue virus (DENV) and Zika virus (ZIKV). We evaluated anti-DENV and anti-ZIKV IgG detection using a multiplex serological platform (the pGOLD assay, Nirmidas, Palo Alto, CA) in patients fromthe Asuncionmetropolitan area in Paraguay, which experiences annual DENV outbreaks but has reported few autochthonous ZIKV infections. Acute-phase sera were tested from 77 patients who presented with a suspected arboviral illness from January to May 2018. Samples were tested for DENV and ZIKV RNA by real-time reverse transcription-PCR, and for DENV nonstructural protein 1 with a lateral-flow immunochromatographic test. Forty-one patients (51.2%) had acute dengue; no acute ZIKV infections were detected. Sixty-five patients (84.4%) had anti-DENVneutralizing antibodies by focus reduction neutralization testing (FRNT50). Qualitative detection with the pGOLD assay demonstrated good agreement with FRNT50 (kappa = 0.74), and quantitative results were highly correlated between methods (P < 0.001). Only three patients had anti-ZIKV-neutralizing antibodies at titers of 1:55-1:80, and all three had corresponding DENV-neutralizing titers > 1:4, 000. Hospitalized dengue cases had significantly higher anti-DENV IgG levels (P < 0.001). Anti-DENV IgG results from the pGOLD assay correlate well with FRNT, and quantitative results may inform patient risk stratification.